2. Search Result
Search Result
Results for "

Trastuzumab

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

5

Peptides

4

Inhibitory Antibodies

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9907
    Trastuzumab
    Maximum Cited Publications
    29 Publications Verification

    Anti-Human HER2, Humanized Antibody

    		 Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody Cancer
    Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab
  • HY-P99547
    Trastuzumab duocarmazine

    (vic)-Trastuzumab duocarmazine

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .
    Trastuzumab duocarmazine
  • HY-P9921
    Trastuzumab emtansine
    2 Publications Verification

    Ado-Trastuzumab emtansine; PRO132365; T-DM 1

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine
  • HY-P9921A
    Trastuzumab emtansine (solution)
    2 Publications Verification

    Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine (solution)
  • HY-138298A
    Trastuzumab deruxtecan
    2 Publications Verification

    DS-8201; DS-8201a

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan
  • HY-138298
    Trastuzumab deruxtecan (solution)
    2 Publications Verification

    DS-8201 (solution); DS-8201a (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan (solution)
  • HY-P9907A
    Trastuzumab (anti-HER2)
    Maximum Cited Publications
    29 Publications Verification

    Anti-Human HER2, Humanized Antibody (PBS)

    		 ADC Antibody EGFR Cancer
    Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-164762
    Trastuzumab rezetecan

    SHR-A1811

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
    Trastuzumab rezetecan
  • HY-P99558
    Timigutuzumab

    GEXMab73; GT-MAb7.3-GEX; Trastuzumab-GEX

    		 EGFR Cancer
    Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
    Timigutuzumab
  • HY-P3147
    IYPTNGYTR

    		Drug Metabolite Others
    IYPTNGYTR, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR can be used to monitor in vivo Trastuzumab metabolism .
    IYPTNGYTR
  • HY-P3147A
    IYPTNGYTR acetate

    		Drug Metabolite Others
    IYPTNGYTR acetate, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR acetate can be used to monitor in vivo Trastuzumab metabolism .
    IYPTNGYTR acetate
  • HY-147408
    Rezetecán

    SHR9265

    		 Topoisomerase ADC Cytotoxin Cancer
    Rezetecán (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecán can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .
    Rezetecán
  • HY-150074
    STING agonist-18

    		Others Cancer
    STING agonist-18 (compound 1a) can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate .
    STING agonist-18
  • HY-151207
    Anticancer agent 81

    		Apoptosis ADC Cytotoxin Cancer
    Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab .
    Anticancer agent 81
  • HY-150074A
    STING agonist-18 diTFA

    		Others Cancer
    STING agonist-18 diTFA (compound 1a) can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate .
    STING agonist-18 diTFA
  • HY-161781
    HVH-2930

    		HSP EGFR Akt Survivin Cancer
    HVH-2930 is an inhibitor for heat shock protein 90 (HSP90). HVH-2930 inhibits cell viability of BT474 (Trastuzumab (HY-P9907) sensitive) and JIMT-1 (Trastuzumab (HY-P9907) resistant), with IC50 of 6.86 μM and 4.42 μM, through downregulation of HSP90 clients HER2, p-HER2, AKT, p-AKT, cyclin D1 and survivin. HVH-2930 exhibits antitumor efficacy in mouse models. HVH-2930 exhibits good pharmacokinetic characteristics in mice .
    HVH-2930
  • HY-130161
    m-PEG4-Br

    		ADC Linker PROTAC Linkers Cancer
    m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907). m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency . m-PEG4-Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.
    m-PEG4-Br
  • HY-130426
    Maleimido-tri(ethylene glycol)-propionic acid

    Mal-PEG3-acid

    		 ADC Linker PROTAC Linkers Cancer
    Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-specific cysteine mutant trastuzumab-A114C conjugation . Maleimido-tri(ethylene glycol)-propionic acid also can be used as a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
    Maleimido-tri(ethylene glycol)-propionic acid
  • HY-160015
    CB07-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of ADCs. ADC conjugated with CB07-Exatecan and trastuzumab inhibits the growth of HER2-positive cancer cells. CB07-Exatecan can be used in cancer research .
    CB07-Exatecan
  • HY-156991
    NODAGA-NHS

    NODA-GA-NHS ester

    		 Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    NODAGA-NHS (NODA-GA-NHS ester) is a [64]Cu chelator and the dissociated form of DOTA-trastuzumab in vivo. NODAGA-NHS was added in 0.1 M borate buffer at a ratio of 5/20/100 and was able to effectively bind trastuzumab (10 mg/mL) (4°C, 20 h). The copper content of the [64]Cu-NODAGA-trastuzumab was up to 80%. After blood was drawn from the caudal vein of mice, [64]Cu-NODAGA-trastuzumab was injected and showed good tumor uptake in mice expressing HER2 tumors, showing good PET imaging tracking ability.
    NODAGA-NHS
  • HY-P3146A
    FTISADTSK acetate

    		Drug Metabolite Cancer
    FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
    FTISADTSK acetate
  • HY-P3146
    FTISADTSK

    		Drug Metabolite Cancer
    FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
    FTISADTSK
  • HY-148773
    MC-Gly-Gly-Phe-Boc

    		ADC Linker Cancer
    MC-Gly-Gly-Phe-Boc is involved in the synthesis of antibody-drug conjugates (ADCs) to Trastuzumab (HY-P9907). MC-Gly-Gly-Phe-Boc can participate in cancer research .
    MC-Gly-Gly-Phe-Boc
  • HY-111895B
    Macropa-NH2 TFA
    3 Publications Verification

    		 Others Others
    Macropa-NH2 TFA is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases .
    Macropa-NH2 TFA
  • HY-W087187
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
    DOTAGA-anhydride
  • HY-P3146S
    FTISADTSK-13C6,15N2 TFA

    		Isotope-Labeled Compounds Cancer
    FTISADTSK- 13C6, 15N2 TFA is 13C- and 15N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
    FTISADTSK-13C6,15N2 TFA
  • HY-49463
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz

    		ADC Linker Neurological Disease
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz is an ADC linker that can be used in the synthesis of ADCs (such as Trastuzumab deruxtecan and U3-1402).
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz
  • HY-153263
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC .
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE
  • HY-129589
    Thailanstatin A
    1 Publications Verification

    		 ADC Cytotoxin Cancer
    Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC50=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC50s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC .
    Thailanstatin A
  • HY-145102
    NCT-58

    		HSP Apoptosis Cancer
    NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells .
    NCT-58
  • HY-W731085
    MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH

    		ADC Linker Cancer
    MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH is an ADC linker that can be combined with the cytotoxic Camptothecin (HY-16560) to form an ADC-related drug-linker conjugate (Drug- Linker Conjugates for ADC).MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is conjugated to Camptothecin, which can further bind to the antibody Trastuzumab (HY-P9907) to form Antibody-Drug Conjugates (ADCs) .
    MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH
  • HY-49929
    MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH

    		ADC Linker Cancer
    MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is an ADC linker that can be combined with the cytotoxic Camptothecin (HY-16560) to form ADC-related drug-linker conjugates (Drug-Linker Conjugates for ADC ).MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is conjugated to Camptothecin, which can further bind to the antibody Trastuzumab (HY-P9907) to form Antibody-Drug Conjugates (ADCs) .
    MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH
  • HY-157169
    IBL-302

    AMU302

    		 Pim mTOR Akt PI3K Cancer
    IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629) .
    IBL-302
  • HY-158005
    Anticancer agent 195

    		Apoptosis Cancer
    Anticancer agent 195 (Compound 10) is an inhibitor for ELF3-MED23 PPI with Ki of 0.68 μM. Anticancer agent 195 induces apoptosis and exhibits antitumor activity .
    Anticancer agent 195
  • HY-145448
    MC-VC-PABC-amide-PEG1-CH2-CC-885

    		E3 Ligase Ligand-Linker Conjugates Cancer
    MC-VC-PABC-amide-PEG1-CH2-CC-885 (compound III) is a neoDegrader, a conjugate of the GSPT1 degrader/molecular glue CC-885 (HY-101488) and a linker. MC-VC-PABC-amide-PEG1-CH2-CC-885 can be conjugated to the antibody DAR3.7 that specifically targets CD56 to synthesize Antibody-Drug Conjugates (ADCs). MC-VC-PABC-amide-PEG1-CH2-CC-885 can also be conjugated to Belantamab (HY-P9980), Daratumumab (HY-P9915), huMy9-6 IgG1, Indatuximab (HY-P990607), Isatuximab (HY-P9976), lintuzumab IgG1, Pertuzumab (HY-P9912), OR000213, Rituximab (HY-P9913), Sacituzumab (HY-P99045), Trastuzumab (HY-P9907)and U3-1784 (HY-P990672) to form conjugates .
    MC-VC-PABC-amide-PEG1-CH2-CC-885

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: